1. Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling
    GUI'E XIE et al, 2016 CrossRef
  2. The anti-lung cancer activities of steroidal saponins of P. polyphylla Smith var. chinensis (Franch.) Hara through enhanced immunostimulation in experimental Lewis tumor-bearing C57BL/6 mice and induction of apoptosis in the A549 cell line.
    Yu Li et al, 2013, Molecules CrossRef
  3. The Inhibitory Effects of Phenolic and Terpenoid Compounds from Baccharis trimera in Siha Cells: Differences in Their Activity and Mechanism of Action
    Cristiane de Oliveira et al, 2013, Molecules CrossRef
  4. Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-кB signaling pathway in colorectal cancer cells
    Bashir A. Yousef et al, 2018, Phytomedicine CrossRef
  5. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer
    Buse Cevatemre et al, 2017, Pharmacological Research CrossRef
  6. Potential role of S100A8 in skin rejuvenation with the 1064-nm Q-switched Nd:YAG laser
    Yan Qin et al, 2018, Lasers Med Sci CrossRef
  7. Pristimerin triggers AIF-dependent programmed necrosis in glioma cells via activation of JNK
    Hongwei Zhao et al, 2016, Cancer Letters CrossRef
  8. null
    Alírica Isabel Suárez et al, 2018 CrossRef
  9. Synthesis and bio-physical characterization of Silver nanoparticle and Ag-mesoporous MnO2 nanocomposite for anti-microbial and anti-cancer activity
    Jothi Ramalingam R. et al, 2017, Journal of Molecular Liquids CrossRef
  10. Investigation of Cytotoxic and Apoptogenic Effects of Terminalia Chebula Hydro-Alcoholic Extract on Glioblastoma Cell Line
    Amir Reza Afshari et al, 2018, Shefaye Khatam CrossRef
  11. In vitro and in vivo anti-leukemia activity of the stem bark of Salacia impressifolia (Miers) A. C. Smith (Celastraceae)
    Ana Carolina B. da C. Rodrigues et al, 2018, Journal of Ethnopharmacology CrossRef
  12. Development and Validation of an HPLC-PDA Method for Biologically Active Quinonemethide Triterpenoids Isolated from Maytenus chiapensis
    Vito Taddeo et al, 2019, Medicines CrossRef
  13. Cis-3-O-p-hydroxycinnamoyl Ursolic Acid Induced ROS-Dependent p53-Mediated Mitochondrial Apoptosis in Oral Cancer Cells
    Ching-Ying Wang et al, 2019, Biomolecules & Therapeutics CrossRef
  14. Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review
    Jia-jun Li et al, 2019, Front. Pharmacol. CrossRef
  15. Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma
    Panagiotis J. Vlachostergios et al, 2013, Cell Biol Toxicol CrossRef
  16. Development and validation of a quantitative liquid chromatography tandem mass spectrometry assay for pristimerin in rat plasma
    Xin Luan et al, 2013, Journal of Chromatography B CrossRef
  17. Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2
    DORRAH DEEB et al, 2014 CrossRef
  18. Oleanolic acid derivatives induce apoptosis in human leukemia K562 cell involved in inhibition of both Akt1 translocation and pAkt1 expression
    Shuhua Pan et al, 2015, Cytotechnology CrossRef
  19. ZnO Nanowire Arrays Exhibit Cytotoxic Distinction to Cancer Cells with Different Surface Charge Density: Cytotoxicity is Charge-Dependent
    Ruizhi Ning et al, 2014, Small CrossRef
  20. Ubiquitin-proteasomal degradation of antiapoptotic survivin facilitates induction of apoptosis in prostate cancer cells by pristimerin
    YONG BO LIU et al, 2014 CrossRef
  21. Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells
    DORRAH DEEB et al, 2015 CrossRef
  22. The cap-translation inhibitor 4EGI-1 induces mitochondrial dysfunction via regulation of mitochondrial dynamic proteins in human glioma U251 cells
    Xin Yang et al, 2015, Neurochemistry International CrossRef
  23. Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression
    Xianbing Peng et al, 2015, Cancer Chemother Pharmacol CrossRef
  24. Pristimerin demonstrates anticancer potential in colorectal cancer cells by inducing G1 phase arrest and apoptosis and suppressing various pro-survival signaling proteins
    BASHIR A. YOUSEF et al, 2016 CrossRef
  25. Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells
    Seon-Ok Lee et al, 2016, BMC Cancer CrossRef
  26. null
    Alak Manna et al, 2016 CrossRef
  27. Inhibition of hTERT in pancreatic cancer cells by pristimerin involves suppression of epigenetic regulators of gene transcription
    Dorrah Deeb et al, 2017 CrossRef
  28. Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant
    Elaine C. D. Gonçalves et al, 2020, Molecules CrossRef
  29. Pristimerin‐induced uveal melanoma cell death via inhibiting PI3K/Akt/FoxO3a signalling pathway
    Fengxia Yan et al, 2020, J Cell Mol Med CrossRef
  30. Mitochondrial pathway is involved in the protective effects of alpha-ketoglutarate on hydrogen peroxide induced damage to intestinal cells
    Qian Jiang et al, 2017, Oncotarget CrossRef
  31. Pristimerin enhances the effect of cisplatin by inhibiting the miR‑23a/Akt/GSK3β signaling pathway and suppressing autophagy in lung cancer cells
    Yingbing Zhang et al, 2019, Int J Mol Med CrossRef
  32. Pristimerin induces apoptosis of oral squamous cell carcinoma cells via G1 phase arrest and MAPK/Erk1/2 and Akt signaling inhibition.
    Haiyan Wu et al, 2019, Oncol Lett CrossRef
  33. Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
    Xuedong Li et al, 2021, DDDT CrossRef
  34. Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances
    Run-Ze Chen et al, 2021, Front. Oncol. CrossRef
  35. Pristimerin improve renal fibrosis by regulating miRNA-145-5p in vitro and vivo study
    Chen XIAO-MEI et al, 2021, Food Sci. Technol CrossRef
  36. Determination of IC50 values of anticancer drugs on cells by D2O – single cell Raman spectroscopy
    Wanxue Lv et al, 2022, Chem. Commun. CrossRef
  37. Natural products in suppressing glioma progression: A focus on the role of microRNAs
    Peyman Tabnak et al, 2022, Phytotherapy Research CrossRef
  38. null
    Ana Carolina B. da C. Rodrigues et al, 2021 CrossRef
  39. Pristimerin, a triterpene that inhibits monoacylglycerol lipase activity, prevents the development of paclitaxel-induced allodynia in mice
    Altaf Al-Romaiyan et al, 2022, Front. Pharmacol. CrossRef
  40. null
    Ana Carolina B. da C. Rodrigues et al, 2022 CrossRef
  41. null
    Heba Almaghrbi et al, 2022 CrossRef
  42. Pristimerin inhibits proliferation, migration and invasion, and induces apoptosis in HCT-116 colorectal cancer cells
    Bashir A. Yousef et al, 2016, Biomedicine & Pharmacotherapy CrossRef
  43. ATTEMPTS TO SYNTHESIZE A TRIMERIC DERIVATIVE OF PRISTIMERIN WITH POTENTIAL ACTIVITY AGAINST CANCER CELLS
    Josana Pereira Dos Santos et al, 2024, Rev. Contemp. CrossRef
  44. Anticancer Potential and Molecular Targets of Pristimerin in Human Malignancies
    Kirti S. Prabhu et al, 2024, Pharmaceuticals CrossRef
  45. Pristimerin exhibits anti-cancer activity by inducing ER stress and AKT/GSK3β pathway through increasing intracellular ROS production in human esophageal cancer cells
    Wei-Bin Hu et al, 2024, Toxicology in Vitro CrossRef